Abstract:Evaluation of survival models to predict cancer patient prognosis is one of the most important areas of emphasis in cancer research. A binary classification approach has difficulty directly predicting survival due to the characteristics of censored observations and the fact that the predictive power depends on the threshold used to set two classes. In contrast, the traditional Cox regression approach has some drawbacks in the sense that it does not allow for the identification of interactions between genomic features, which could have key roles associated with cancer prognosis. In addition, data integration is regarded as one of the important issues in improving the predictive power of survival models since cancer could be caused by multiple alterations through meta-dimensional genomic data including genome, epigenome, transcriptome, and proteome. Here we have proposed a new integrative framework designed to perform these three functions simultaneously: (1) predicting censored survival data; (2) integrating meta-dimensional omics data; (3) identifying interactions within/between meta-dimensional genomic features associated with survival. In order to predict censored survival time, martingale residuals were calculated as a new continuous outcome and a new fitness function used by the grammatical evolution neural network (GENN) based on mean absolute difference of martingale residuals was implemented. To test the utility of the proposed framework, a simulation study was conducted, followed by an analysis of meta-dimensional omics data including copy number, gene expression, DNA methylation, and protein expression data in breast cancer retrieved from The Cancer Genome Atlas (TCGA). On the basis of the results from breast cancer dataset, we were able to identify interactions not only within a single dimension of genomic data but also between meta-dimensional omics data that are associated with survival. Notably, the predictive power of our best meta-dimensional model was 73% which outperformed all of the other models conducted based on a single dimension of genomic data. Breast cancer is an extremely heterogeneous disease and the high levels of genomic diversity within/between breast tumors could affect the risk of therapeutic responses and disease progression. Thus, identifying interactions within/between meta-dimensional omics data associated with survival in breast cancer is expected to deliver direction for improved meta-dimensional prognostic biomarkers and therapeutic targets.

Bayesian Variable Selection for Parametric Survival Model with Applications to Cancer Omics Data

Unbiased Prediction and Feature Selection in High-Dimensional Survival Regression

Bayesian Variable Selection In Semiparametric Proportional Hazards Model For High Dimensional Survival Data

Penalized Bayesian forward continuation ratio model with application to high-dimensional data with discrete survival outcomes

Gaussian process regression for survival time prediction with genome-wide gene expression

Survival Prediction and Variable Selection with Simultaneous Shrinkage and Grouping Priors

Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates.

Identifying Oncogenes As Features for Clinical Cancer Prognosis by Bayesian Nonparametric Variable Selection Algorithm

Multivariate Bayesian structured variable selection for pharmacogenomic studies

Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer

A Novel Attention-Mechanism Based Cox Survival Model by Exploiting Pan-Cancer Empirical Genomic Information

Stochastic EM algorithm for generalized exponential cure rate model and an empirical study

Conditional screening for ultra-high dimensional covariates with survival outcomes

Survival-supervised latent Dirichlet allocation models for genomic analysis of time-to-event outcomes

A Simplified Stochastic EM Algorithm for Cure Rate Model with Negative Binomial Competing Risks: An Application to Breast Cancer Data

Variational Bayes for high-dimensional proportional hazards models with applications within gene expression

Bayesian Joint Modeling of Multivariate Longitudinal and Survival Data with an Application to Diabetes Study.

Bayesian parametric models for survival prediction in medical applications

Personalized Risk Prediction for Cancer Survivors: A Bayesian Semi-parametric Recurrent Event Model with Competing Outcomes

A Bayesian joint model of multiple longitudinal and categorical outcomes with application to multiple myeloma using permutation-based variable importance

Integrative survival analysis of breast cancer with gene expression and DNA methylation data